Betrixaban maleate

• CAT Number: L010294
• CAS Number: 936539-80-9
• Molecular Formula: C27H26ClN5O7
• Molecular Weight: 568
• Purity: ≥95%
• Target: Factor Xa
• IUPAC Name: (Z)-but-2-enedioic acid;N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
• InChI: InChI=1S/C23H22ClN5O3.C4H4O4/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20;5-3(6)1-2-4(7)8/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31);1-2H,(H,5,6)(H,7,8)/b;2-1-
• InChIKey: DTSJEZCXVWQKCL-BTJKTKAUSA-N

Betrixaban maleate(CAT: L010294) is an anticoagulant compound used for the prevention and treatment of venous thromboembolism (VTE) in high-risk patients. As a selective oral factor Xa inhibitor, Betrixaban works by blocking the activity of factor Xa, a key enzyme in the blood clotting cascade, thereby reducing the risk of clot formation. The maleate salt form enhances its stability and solubility, making it suitable for oral administration. Betrixaban maleate is particularly valuable in long-term anticoagulation therapy, offering a safer profile in terms of bleeding risks compared to traditional anticoagulants, and is a subject of ongoing research for broader therapeutic applications in cardiovascular disease management.